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ABSTRACT 
Background. Treatment guidelines recommend regular inhaled corticosteroid and long-acting β2 
agonist combination plus PRN rapid-acting bronchodilators for patients with moderate persistent 
asthma. We investigated whether  PRN symptom-driven budesonide/formoterol combination would 
be as effective as regular budesonide/formoterol combination plus PRN symptom-driven 
terbutaline. 
Methods. After a six-week run-in period of regular budesonide/formoterol plus PRN terbutaline, 
866 patients with stable moderate asthma were randomly assigned according to a list prepared with 
the use of a random-number generator and a balanced-block design stratified according to centre to 
receive placebo twice daily plus PRN combination of 160 µg budesonide/4·5 µg formoterol (PRN 
budesonide/formoterol therapy) or twice-daily 160 µg budesonide/4·5 µg formoterol combination 
plus symptom-driven 500 µg terbutaline  (regular budesonide/formoterol therapy) for one year. The 
primary outcome was time to first treatment failure during the one year treatment, and the power of 
the study was calculated on the rate of treatment failure, and the analysis was performed on the 
intention to treat population. 
Findings. Compared to regular budesonide/formoterol therapy, PRN budesonide/formoterol 
therapy was associated with lower probability of patients with no treatment failure (Kaplan Meier 
estimates, 53·6% vs 64·0%; difference: 10·3%, 95% CI: 3·2%, 17·4%, pre-defined non-inferiority 
limit: 9%); earlier treatment failure (first quartile, 11·86 versus 28·00 days); higher drop-out rates 
(Kaplan Meier estimates, 34·0% vs 25·9%, p=0·009).The difference in treatment failures was 
largely due to nocturnal awakenings (82 patients in the PRN budesonide/formoterol group and 44 in 
the regular budesonide/formoterol group). PRN budesonide/formoterol therapy was also inferior in 
most secondary outcomes. Both treatment regimens were well tolerated.  
Interpretation. In patients with moderate asthma, PRN budesonide/formoterol therapy is less 
effective than the guidelines-recommended regular budesonide/formoterol therapy, even if the 
differences are small. (ClinicalTrials.gov number NCT00849095). 
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Funding: The study was granted by the Italian Medicines Agency, AIFA, (grant FARM6BWSF9). 
Drugs were donated by AstraZeneca.  
 
INTRODUCTION 
The 2014 revision of the Global Initiative for Asthma (GINA) guidelines recommends first 
assessing the level of asthma control and then planning treatment accordingly.1 For patients not 
controlled by low-dose inhaled corticosteroid (ICS), guidelines recommend a combination of low-
dose ICS and a long-acting β2-agonist (LABA) plus a rapid-acting β2-agonist  for symptom relief, or 
inhaled ICS/rapid-acting LABA combination both regular and for symptom relief. This approach, 
called same maintenance and reliever therapy (SMART), achieves similar asthma control but more 
effective reduction of exacerbations in moderate to severe asthmatics.2-10  
The symptom-driven use of an ICS/short-acting β2-agonist (SABA) or an ICS/LABA 
combination in the absence of any regular maintenance treatment are considered effective 
alternatives to regular ICS plus PRN SABA in patients with intermittent or mild asthma.11-12  In 
subjects with mild persistent asthma, i.e., controlled by regular low-dose ICS,  the PRN 
combination of beclomethasone (BDP) and the SABA salbutamol with no regular treatment is non 
inferior to regular low-dose BDP plus PRN salbutamol.13 The rationale for preferring a symptom-
driven approach is that it allows titration both the ICS and the LABA according to the needs of the 
patient, and is associated with lower cumulative exposure to both bronchodilators and ICS, and 
might reduce the impact of low adherence to regular treatment commonly found in “real life”.11,12,14 
In addition,  treatment with a steroid together with a bronchodilator for symptom relief may be 
more effective that a bronchodilator alone, as it may reverse not only bronchoconstriction but also 
the transient acute airway inflammation15-18  associated with the development of symptoms11,19-22 
and thus it may improve asthma control and reduce the need for regular treatment.   
No previous study has investigated whether moderate asthmatics, i.e. patients whose asthma 
is not controlled by low-dose ICS but is adequately controlled by an ICS/LABA combination, can 
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be equally controlled by a symptom-driven ICS/LABA combination in the absence of regular 
maintenance treatment.   
In this one-year study, we investigated whether treatment failure could be prevented in 
moderate asthmatics receiving regular placebo plus PRN budesonide/formoterol combination versus 
the regular budesonide/formoterol combination plus PRN terbutaline.  
 
METHODS  
 
Design and study population  
This was a multicentre, randomised, placebo-controlled, double-blind, parallel group study 
(eFigure 1, Appendix). The study population consisted of adults with moderate persistent asthma, 
i.e., according to 2006 GINA guidelines,23 who were either not controlled by low-dose ICS 
(≤500µg BDP/day or equivalent; 72·7%)  or controlled by a fixed combination of low-dose 
ICS+LABA b.i.d during the 2 months before the study (27·3%). Asthma was considered not 
adequately controlled with low-dose ICS if patients reported > two/week daytime symptoms, > 
two/week need for rescue treatment, any nocturnal symptoms or awakening, any limitation of 
activities, and use of oral corticosteroids in the last month before enrolment. By contrast, asthma 
was considered adequately controlled in the patients who had initiated treatment with low-dose 
ICS/LABA combination  in the last year because asthma was not controlled by low-dose ICS, and 
that in the two month before the study reported ≤ two/week daytime symptoms, ≤ two/week need 
for rescue treatment, no nocturnal symptoms or awakening, no limitation of activities, and no use of 
oral corticosteroids. Main exclusion criteria were: inability to carry out pulmonary function testing;  
moderate severe asthma associated with reduced lung function; history of near-fatal asthma and/or 
admission to intensive care unit because of asthma; three or more courses of oral corticosteroids or 
hospitalisation for asthma during the previous year; diagnosis of COPD as defined by the GOLD 
guidelines; evidence of severe asthma exacerbation or symptomatic infection of the airways in the 
previous 8 weeks; current smokers or recent (<1 year) ex-smokers, defined as smoking at least 10 
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pack/years; history or current evidence of heart failure, coronary artery disease, myocardial 
infarction, severe hypertension, or cardiac arrhythmias; diabetes mellitus. Further details of entry 
and exclusion criteria are given in eTable 1 of the Appendix. 
Eligible patients entered a six-week run-in period, during which they received open-label 
b.i.d. 160/4·5 µg budesonide/formoterol combination plus PRN 500 µg terbutaline. At the end of 
run-in, patients with  controlled asthma during the last 14 days of the run-in were randomised to 
receive either b.i.d. placebo plus PRN 160/4·5 µg budesonide/formoterol combination (PRN 
budesonide/formoterol) or b.i.d. 160/4·5 µg budesonide/formoterol combination plus PRN 500 µg 
terbutaline (regular budesonide/formoterol). Patients were not given a written plan of action to 
guide the as-needed use of study drugs but were simply instructed orally to use them any time they 
were needed for relief of symptoms. Patients were not supplied with OCS or additional ICS to keep 
at home for self-administration in case of asthma deterioration, but instructed, as per current clinical 
practice, to seek for medical attention/investigator contact (unscheduled visit) in case of 
uncontrolled clinical condition.  At the end of one year of treatment, patients underwent a 6-week 
follow-up  open-label SMART therapy with 160/4·5 µg budesonide/formoterol with the aim of 
assessing whether maximizing treatment would modify the level of control observed at the end of 
the study (eFigure 1, Appendix). Up to eight additional PRN inhalations/day were allowed for the 
entire study duration. No other anti-asthma drug was allowed. All drugs were prepared and given by 
the dry-powder inhaler Turbohaler. Treatment compliance was assessed by the clinical investigator 
at each visit by asking the  patients to return  study drug devices and diary cards. Diary cards were 
reviewed and correct use of the device was assessed at each visit. Compliance to medication was 
checked by counting the remaining doses (dose-counter) in each returned DPI at the end of the 
study period (visit 9) and reporting the number in the CRF. Compliance to treatment was expressed 
as % of expected number of doses actually taken in the last 8 weeks.  
As specified in the protocol, patients were allowed to receive by the investigators or by the 
family doctor additional medication for the treatment of the worsening asthma, including additional 
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"open label" courses of inhaled bid and/or oral/systemic corticosteroids. Patients were also 
recommended to stop study medication during exacerbations. Investigators were asked to annotate 
in the CRF the treatments they received for the exacerbations.  Patients were not withdrawn from 
the study after the exacerbation, unless decided by the patient, family physician, investigator.  
Efficacy outcomes 
The primary outcome of the study was the time to treatment failure and the power of the 
study was based on the rate of treatment failure at one year (vide infra). Treatment failure was 
defined as the occurrence of one of the following: hospitalisation, unscheduled medical visits for 
asthma, use of systemic corticosteroids or open-label use of ICS for asthma prescribed by a 
physician, two nocturnal awakenings on two consecutive days,  ≥4 additional puffs/day compared 
with baseline on two consecutive days, refusal of the patient to continue because of dissatisfaction 
with treatment, or treatment stopped by the physician for safety reasons. Secondary outcomes were: 
time to treatment failure, time to drop-out, use of rescue medication, asthma control, quality of life, 
daily morning/evening PEF, measured by the patient; pre-bronchodilator forced vital capacity 
(FVC), FEV1, FEV1/vital capacity, and FEV1/FVC; post-bronchodilator FEV1; asthma symptom 
scores; rescue medications; Asthma Control Questionnaire24; and Asthma-Related Quality of Life 
Questionnaire.25 Secondary safety outcomes were adverse events and morning serum cortisol 
(Appendix). 
Statistics 
All statistical analyses and data processing were performed using Statistical Analysis 
Systems (SAS®) Software (release 9.2) on a Windows 7 operating system. 
The rate of patients in the regular budesonide/formoterol group with treatment failure at one 
year was estimated at 35%, and a non-inferiority margin of 9% at one year was considered 
clinically acceptable, based on an estimated effect size of 17%.7,26 A total of 355 treatment failures 
(in patients with at least one) were required to test the non-inferiority (one-sided test at 0·025 
significance level) of the time to treatment failure of the PRN budesonide/formoterol group versus 
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the regular combination group, with a power of at least 80%. A total of 860 evaluable patients, 430 
in each group, were required to satisfy the above hypothesis.   
 Kaplan-Meier estimates were used to evaluate the time to treatment failure and the 
probability of patients with no treatment failure at 1 year. Time to treatment failure was also 
analysed by using a Cox proportional hazards regression model, including only treatment in the 
model. 
 Methods for the sensitivity analyses of the primary outcome, and ANCOVA models for 
secondary quantitative endpoints are described in the Appendix. A post-hoc analysis was performed 
to evaluate the effects of baseline risk factors/covariates on the probability of treatment failure by 
means of a logistic analysis. The primary endpoint was assessed both in the ITT and PP population, 
where the  ITT analysis included all randomized patients who received at least one administration 
of the study medication and who had at least one available post-baseline efficacy evaluation and the 
PP population excluded from the ITT the efficacy data collected after the start date of the major 
protocol deviation. All secondary endpoint were analysed in the ITT population. 
 
Randomisation and masking 
Patients were randomly assigned to a treatment group according to a list prepared with the 
use of a random-number generator and a balanced-block design (block size = 4) stratified according 
to centre. 
DPI devices were identical in shape and used in all groups to ensure a double-blind design. 
The inhalation devices containing regular treatment (budesonide/formoterol combination or 
placebo) were white, whereas those for as-needed treatment (terbutaline or budesonide/formoterol 
combination) were yellow. 
A package insert written in Italian containing the instructions for use was included in each 
test treatment. Patients were instructed to take one inhalation in the morning and one inhalation in 
the evening from the white device, and one or more inhalation when needed for symptoms relief 
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from the yellow device. Patients were individually instructed to use the DPIs with the support of the 
package insert. 
The protocol was approved by the institutional review board for each centre, and all 
participants provided written informed consent. The study was conducted in accordance with Good 
Clinical Practice guidelines and the Declaration of Helsinki. The clinical trial is registered with 
ClinicalTrials.gov  (NCT00849095). 
Role of the funding source 
The study was funded by the Italian Medicines Agency (www.agenziafarmaco.gov.it, 
Agenzia Italiana del Farmaco, AIFA, FARM6BWSF9) of the Italian Ministry of Health 
(www.salute.gov.it). All drugs were donated by AstraZeneca (AstraZeneca S.p.a. Basiglio, Milano, 
Italy), which had no role in the study design. 
Data were collected by the clinical investigators, analysed by CROS NT (Verona, Italy), and 
discussed by the clinical investigators.  AstraZeneca had no role in data collection and analyses, and 
in drafting the manuscript, nor was informed of the results of the study.  The corresponding author 
had full access to all of the data and the final responsibility to submit for publication. 
 
RESULTS  
A total of 1,010 patients were screened, and 866 were randomised (424 in the PRN 
budesonide/formoterol group and 442 in the regular budesonide/formoterol group). Figure 1 shows 
the disposition of patients. The number of patients who actually received treatment (safety 
population) was 419 in the PRN budesonide/formoterol group and 437 in the regular 
budesonide/formoterol group. The intention-to-treat (ITT) population included 394 and 423 
patients, respectively, and the per protocol (PP) population included 393 and 422 patients, 
respectively.  
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Treatment groups were well matched in demographic and clinical characteristics at baseline 
(Table 1).  Compliance to treatment  at the end of the study period (visit 9) was of 85 % (SD: 27%) 
and of  83% (SD: 26%) in the PRN and regular budesonide/formoterol groups, respectively. 
 
Primary efficacy outcome 
Compared to regular budesonide/formoterol  therapy, patients in the PRN 
budesonide/formoterol group had shorter time to treatment failure (Table 2 and Figure 2)  and  
higher probability of treatment failure (Kaplan Meier estimates, 53·6% vs 64·0%; difference: 
10·3%, 95% CI: 3·2%, 17·4%, pre-defined non-inferiority limit: 9%) at one year (Table 2 and 
Figure 2)  in the ITT population analysis . The hazard ratio between the two groups was 1·49 (95% 
CI, 1·19 to 1·87). The two curves for the 2 groups were resulted to be parallel and this confirmed 
the proportional hazards assumption. In addition we tested the correlation of the scaled Schoenfeld 
residuals on functions of time for both the ITT and PP population. The Pearson correlation was not 
statistically significant and for this reason there was not a violation of the proportional hazard 
assumption. 
The cumulative number of patients experiencing treatment failure during the one-year study 
period was 170 (43·1%) in the PRN budesonide/formoterol group and 139 (32·9%) in the regular 
budesonide/formoterol group.  
The results observed in the PP analysis were consistent with those in the ITT population 
(eTable 2, Appendix). The pre-planned sensitivity analyses, which treated  drop-outs as treatment 
failures (eFigure 2, Appendix), confirmed the robustness of the results of the primary outcome.  The 
most common reason for treatment failure was two nocturnal awakening on two consecutive days 
(82 patients in the PRN budesonide/formoterol group and 44 in the regular budesonide/formoterol 
group). This was the only component of the composite primary outcome that differed significantly 
between groups (p<0·001) (Table 2a). The mean percentage of days with nocturnal awakenings was 
16·17 (SD: 23·94) and 7·94 (SD: 16·07) in the  PRN budesonide/formoterol and in the regular 
budesonide/formoterol group respectively. Female sex and smoking habit in the PRN 
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budesonide/formoterol group, and baseline Asthma Control Questionnaire score overall and in both 
groups, were the factors significantly associated with higher risk of failure (Figure 3). 
Secondary efficacy outcomes 
The time to drop-out was shorter in the PRN budesonide/formoterol group (28 versus 48 
days, representing the time until at least 25% of the patients [first quartile] dropped out of the study; 
p=0·009 between groups in the log-rank test). Appendix, eFigure 3, shows the Kaplan-Meier plot 
for the time to drop-out in the ITT population. The cumulative number of patients who dropped out 
at the end of the randomised treatment phase was 133 (31·4%) in the PRN budesonide/formoterol 
group and 108 (24·4%) in the regular budesonide/formoterol group; Kaplan Meier estimates, 34·0% 
vs 25·9%, p=0·009). 
Table 2b shows the results of the other secondary outcomes. From baseline to the end of 
treatment in the randomised phase of the study, there were significant differences between the two 
groups, in favour of regular budesonide/formoterol therapy.   
After the follow-up period with open-label SMART budesonide/formoterol therapy (eTable 
3, Appendix, ) only morning PEF (p=0·02), number of puffs of rescue medication (p=0·01), and 
percentage of days without use of rescue medication (p=0·004) were still significantly different in 
favour of regular budesonide/formoterol therapy. 
Safety 
Patients on PRN budesonide/formoterol combination used significantly more rescue 
medications, and the difference, albeit small, remained significant even at the end of the follow-up 
(Table 2b; eTable 3, Appendix).  The estimated cumulative dose of budesonide (116·8 vs 24·5 
mg/year) and formoterol (3·2 mg vs 0·69 mg/year) was obviously larger in patients treated with 
regular budesonide/formoterol combination.   
Apart from the number of patients with oropharyngeal pain, he number of patients with 
treatment-emergent adverse events (TEAEs) was no different between the two groups (Table 3). 
Similarly, there were no differences in the number of patients with adverse reactions. Worsening of 
asthma was the most common TEAE: 48 patients (11·5%) in the PRN budesonide/formoterol group 
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and 40 (9·2%) in the regular budesonide/formoterol group (Table 3). From baseline to the end of 
the treatment period, morning serum cortisol showed no evidence of adrenal suppression in either 
group (data not shown). 
 
DISCUSSION  
In this one-year, randomised, double-blind, clinical trial conducted in moderate asthmatics, 
PRN budesonide/formoterol was inferior to regular budesonide/formoterol combination plus PRN 
terbutaline in preventing treatment failure. These results confirm the guideline recommended 
regular LABA/ICS combination treatment for patients not adequately controlled by regular ICS.1  
Nocturnal awakenings were the only  component of treatment failure  that was not protected by the 
PRN budesonide/formoterol therapy, most likely either because of lack of protection offered by the regular 
treatment or lack of prompt reversal of nocturnal symptoms by the PRN budesonide/formoterol combination 
treatment  The overall increased number of nocturnal awakening in the PRN budesonide/formoterol group 
was 38 episodes of  nocturnal awakening in two consecutive nights in one year for the 394 patients in the 
ITT population, i.e. an average risk of one episode of nocturnal awakening in two consecutive night per 
patient in  ten years, which may be considered of limited clinical relevance. The other difference between 
the two treatments was the higher drop-out from the study in patients on PRN 
budesonide/formoterol treatment (41·3% in the PRN budesonide/formoterol group and 31·2% in the 
regular budesonide/formoterol group). The drop-out was reported to be not related to efficacy or 
safety reasons,  but mainly to consent withdrawn (11·5%  vs 14·6%) and other logistic reasons. In a 
relatively young and actively working population, it is not totally surprising  that the willingness 
(and possibility) to follow the strict rules-visit intervals- of a RCT for one entire year may be too 
demanding, and thus patients withdrew their consent (the main dropout reason; the same for logistic 
reasons), especially in a non-sponsored study, like the present one, where patients received no 
payment nor expense reimbursement for the participation to the study.  However, the difference 
between the two groups (5·4%  vs 8·0%) further suggest inferiority of the PRN 
budesonide/formoterol treatment. The results of the sensitivity analyses that took into account the 
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study drop-outs confirmed the results of the primary analysis, excluding that they might have been 
affected by the different drop out. 
Because of the characteristics of the population examined, i.e., patients with moderate 
asthma well controlled by the regular ICS/LABA combination—hence, not at high risk of 
exacerbations—the primary outcome of our study was rate to treatment failure. Indeed there were 
only 117 severe exacerbations (defined as treatment with steroids and/or admission to the 
emergency room/hospital7) in 817 patients during the one-year study (0·143 per patient per year): 
53 (none hospitalized) in the PRN budesonide/formoterol group (0·135 per patient per year) and 64 
(4 hospitalized) in the regular budesonide/formoterol group (0·151 per patient per year). Thus, both 
therapies were associated with a very low incidence of severe exacerbations, possibly because they 
were both effective in controlling exacerbations.  
Poor adherence in the regular treatment might have reduced the difference in medication use 
between the two groups, thereby contributing the small differences in outcomes at the end of the 
study. In fact, Patel et al8 recently reported that adherence is lower in regular compared to SMART 
treatment and falls progressively over six and 12 months, suggesting that poor adherence to regular 
maintenance treatment might have influenced the small differences in outcomes that we observed in 
our study. However, the differences observed in our study likely reflect what would happen in real 
life by adopting the two different strategies compared in this study. 
After the one-year randomised treatment, both groups of patients received a six-week 
SMART treatment with both maintenance and reliever budesonide/formoterol therapy to reverse 
uncontrolled components of asthma, if any. Both groups improved clinically and in most 
measurements of lung function made in the clinic (FVC, FEV1, and PEF). These values returned to 
baseline, suggesting there had been no irreversible decline in lung function. However, morning PEF 
measured by the patient at home decreased significantly in the PRN budesonide/formoterol  group 
and did not return to baseline after six weeks of SMART treatment. The reasons for the discrepancy 
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between measurements of lung function made by the patient and in the clinic remain unclear.27 
Although the decrease in morning PEF may suggest that the PRN budesonide/formoterol therapy 
may be associated with a decline in pulmonary function that was not reversible even after six weeks 
of SMART treatment with budesonide/formoterol, the fact that such a decline was not observed in 
clinically assessed PEF, FVC and FEV1 is reassuring. 
The use of rescue medication and the percentage of days without the use of rescue 
medication remained significantly different between groups at the end of the six-week SMART 
follow-up therapy, suggesting that long-term PRN therapy may be associated with some persistent 
small reduction of control. 
As expected, the number of patients with adverse reactions was low in both groups and, 
apart from the predictable oropharyngeal pain possibly related to the regular use of inhaled steroids,  
there were no other difference between groups, suggesting that safety is not an issue in considering 
the two alternative therapies, at least from a one-year perspective. In particular, the use of a less 
intensive regimen in the PRN budesonide/formoterol group did not result in a lower risk of adverse 
events compared to the regular budesonide/formoterol group.  
The study had some weaknesses. Two centers that initially agreed to participate in the study 
withdrew afterwards their willingness to participate/participation for logistic at local reasons. No 
patients were randomized in these centers and entered in the analysis. Also, due to the limited 
budget, monitoring of the centers was mainly made via teleconferences/internet and not with direct 
site-visits as usually performed in pharmaceutically sponsored randomized clinical trials. Moreover, 
paper diary card consisted a limitation for the completeness of the data related to  PEF/symptoms 
data. This problem is well known in clinical research and the use of ePRO is more frequent to limit 
this aspect. The limitation of the budget was not allowing though the use of these tools. 
In conclusion, the results of this study show that PRN budesonide/formoterol is inferior to 
regular budesonide/formoterol plus PRN terbutaline in preventing treatment failure and in 
maintaining control. However, because the differences were small and the level of control remained 
above partially controlled asthma,1,23 we speculate that in recommending the regular combination 
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treatment according to guidelines, the results of this study could be discussed with the patient, 
particularly reinforcing the recommendation of regular treatment with LABA/ICS combination to 
female patients and to patients with a significant smoking history who have a higher risk of loss of 
asthma control with PRN combination treatment28 (Figure 3). Other patients could be presented 
with the advantages of a PRN treatment (convenience, lower cumulative dose of medications, 
potential long-term safety) to balance the disadvantages (lower level of control of asthma with 
occasional nocturnal awakening, increased use of rescue medication).  
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Table 1. Demographic and clinical characteristics of patients at baseline (ITT population) 
  PRN 
budesonide/formoterol 
(N=394) 
Regular 
budesonide/formoterol 
(N=423) 
Sex, N (%) 
   Males 
   Females 
  
153 (38·8%) 
241 (61·2%) 
  
185 (43·7%) 
238 (56·3%) 
Age, years (mean ± SD) 42·1 ± 12·8 (N=392)  43·2 ± 12·6 (N=423)  
Ethnic origin, N (%) 
  White 
  Asian 
  Black 
  Other 
  Missing 
  
382 (97·0%) 
5 (1·3%) 
4 (1·0%) 
3 (0·8%) 
0 (0·0%) 
  
415 (98·1%) 
3 (0·7%) 
1 (0·2%) 
3 (0·7%) 
1 (0·2%) 
Weight, kg (mean ± SD) 71·93 ± 16·33 (N=393) 73·10 ± 16·01 (N=422) 
Height, cm (mean ± SD) 166·6 ± 9·60 (N=393) 166·5 ± 9·80 (N=422) 
BMI, kg/m2 (mean ± SD) 25·87 ± 5·35 (N=393) 26·31 ± 5·09 (N=422) 
Asthma duration, years (mean ± SD) 10·95 ± 10·27 (N=393)   10·99 ± 10·68 (N=419)   
Morning PEF, L/min (mean ± SD) 402·02 ± 121·50 (N=363) 414·11 ± 120·08 (N=395) 
Evening PEF, L/min (mean ± SD) 406·51 ± 121·66 (N=362) 419·99 ± 121·03 (N=393) 
Pre-bronchodilator FEV1, L (mean ± SD) 2·91 ± 0·84 (N=393)  2·95 ± 0·81 (N=419) 
Pre-bronchodilator FEV1 Pred, % (mean ± SD) 93·59 ± 21·54 (N=393) 94·58 ± 14·33 (N=418) 
Post-bronchodilator FEV1, L (mean ± SD) 3·01 ± 0·85 (N=379) 3·06 ± 0·83 (N=406) 
Post-bronchodilator FEV1 Pred, % (mean ± SD) 96·70 ± 22·00 (N=379)  97·73 ± 14·76 (N=405) 
Pre-bronchodilator FVC, L (mean ± SD) 3·86 ± 1·03 (N=393) 3·92 ± 1·02 (N=419) 
Asthma symptoms, score (mean ± SD) 0·11 ± 0·30 (N=364) 0·06 ± 0·18 (N=388) 
Rescue medication, puffs/day (mean ± SD) 0·13 ± 0·52 (N=352) 0·06 ± 0·21 (N=377) 
ACQ, score (mean ± SD) 0·57 ± 0·68 (N=375) 0·52 ± 0·64 (N=401) 
AQLQ, score (mean ± SD) 6·03 ± 0·94 (N=363) 6·00 ± 0·81 (N=401) 
Use of regular LABA/ICS combination therapy in 
the last year, N (%) 
104 (26·4%) 119 (28·1%) 
 
N = number of patients; ACQ = Asthma Control Questionnaire; AQLQ = Asthma-Related Quality of Life 
Questionnaire. 
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Table 2. Primary and secondary outcomes 
Table 2a. Primary outcome: time to treatment failure in the ITT population 
  PRN 
budesonide/ 
formoterol 
(N=394) 
Regular  
budesonide/ 
formoterol  
(N=423) 
 
Probability of no treatment failure   at 1 year,  
Kaplan Meier estimate (SE) 
 
 
0·536 (0·026) 
 
 
0·640 (0·025) 
Difference between the PRN budesonide/formoterol 
therapy and the regular budesonide/formoterol therapy 
     Two-sided 95% CI 
 
Time to treatment failure during treatment period 
Hazard ratio 
     Two-sided 95% CI 
 
0·103 
0·032, 0·174 
 
1·491 
1·192, 1·866 
  
 
 
Patients who experienced at least one treatment failure  
 
 
170 (43·1%) 
 
 
139 (32·9%) 
Reasons for first treatment failure (N)   
     Hospitalisation 0 3 
     Treatment stopped for safety reasons (physician’s 
     judgment) 
24 23 
     Refusal to continue because of patient dissatisfaction 
     with treatment 
6 4 
     Episodes of wo nocturnal awakenings on two  
consecutive days 
82 44 
     Unscheduled medical visit for asthma worsening 6 8 
     Use of rescue medication 17 18 
     Use of systemic CS or ICS for asthma worsening 51 59 
                       Use of systemic CS for asthma  worsening                 31 31 
                       Use of  ICS for asthma worsening                                20 28 
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Table 2b. Secondary outcomes (ITT population)  
  PRN 
budesonide/formoterol 
(N=394) 
Regular 
budesonide/formoterol 
(N=423) 
Difference between 
adjusted means (Regular 
vs PRN) 
 
Pulmonary function   
 
Morning PEF, L/min(N)* 
    Mean change ± SD  
    95% CI 
    P-value 
191 
–22·73 ± 55·26 
–31·18 to –14·29 
 
234 
–2·61 ± 41·89 
–8·25 to 3·04 
 
 
23·127 
13·406, 32·847   
p<0·001 
Evening PEF, L/min (N)* 
    Mean change ± SD  
    95% CI 
    P-value 
190 
–21·39 ± 56·27 
–30·01 to –12·76 
 
230 
–4·21 ± 43·62 
–10·15 to 1·74 
 
 
19·882 
9·766, 29·998 
p<0·001 
FEV1, L (N) 
    Mean change ± SD  
    95% CI 
    P-value 
244 
–0·16 ± 0·37 
–0·20 to –0·11 
 
305 
–0·01 ± 0·34 
–0·05 to 0·03 
 
 
0·146  
0·088, 0·204 
p<0·001 
FEV1 pred, % (N) 
    Mean change ± SD  
    95% CI 
    P-value 
Post-bd FEV1, L (N) 
    Mean change ± SD  
    95% CI 
    P-value 
244 
–3·47 ± 12.40 
–5·03 to –1·91 
 
232 
–0·08± 0·31 
–0·12 to –0·04 
 
305 
–0·02 ± 11·95 
–1·38 to 1·33 
 
294 
0·06 ± 0·34 
0·02 to 0·10 
 
 
3·605  
1·715, 5·494 
p<0·001 
 
0·137 
0·080, 0·194 
p<0·001 
Post-bd FEV1 pred, % (N) 
    Mean change ± SD  
    95% CI 
    P-value 
FVC, L (N) 
    Mean change ± SD  
    95% CI 
    P-value 
232 
–0·81 ± 12.76 
–2·48 to 0·86 
 
244 
–0·10 ± 0·39 
–0·15 to –0·05 
 
293 
2·33 ± 12·65 
0·85 to 3·81 
 
305 
–0·02 ± 0·38 
–0·06 to 0·03 
 
 
3·082  
0·998, 5·166 
p=0·004 
 
0·079 
0·015, 0·142 
p=0·015 
PEF, L/min (N)** 
    Mean change ± SD  
    95% CI 
    P-value 
244 
–33·96 ± 97·22  
–46·22 to –21·70 
 
305 
–13·64 ± 99·40 
–24·91 to –2·36 
 
 
20·863  
6·921, 34·804 
p=0·003 
Asthma symptoms 
   
Symptoms score (N)* 
    Mean change ± SD  
    95% CI 
    P-value 
194 
0·14 ± 0·43 
0·07 to 0·20 
 
225 
0·05 ± 0·29 
0·01 to 0·10 
 
 
–0·103 
–0·177, –0·029  
p=0·006 
% of days without symptoms (N)* 
    Mean change ± SD  
    95% CI 
    P-value 
194 
–15·46 ± 37·29 
–21·14 to –9·78 
 
225 
–4·95 ± 27·75 
–8·81 to –1·09 
 
 
11·886 
5·409, 18·363 
p<0·001 
Use of rescue medication 
   
Rescue medication, puffs/day (N)* 
    Mean change ± SD  
    95% CI 
    P-value 
187 
0·42 ± 0·82 
0·29 to 0·55 
 
219 
0·12 ± 0·52 
0·05 to 0·19 
 
 
–0·304 
–0·499, –0·159 
p<0·001 
% of days without rescue (N)* 
    Mean change ± SD  
    95% CI 
    P-value 
187 
–23·80 ± 38·51 
–29·83 to –17·77 
 
219 
–6·38 ± 25·33 
–9·95 to –2·82 
 
 
18·036 
11·292, 24·779 
p<0·001 
Asthma control 
   
ACQ, score (N) 
    Mean change ± SD  
    95% CI 
231 
0·25 ± 0·92 
0·12 to 0·37 
293 
0·06 ± 0·74 
–0·03 to 0·15 
 
–0·207 
–0·337, –0·077 
22 
 
    P-value 
  p=0·002 
% of days of asthma control (N)* 
    Mean change ± SD  
    95% CI 
    P-value 
185 
–21·65 ± 40·85 
–28·07 to –15·23 
 
217 
–6·53 ± 29·67 
–10·74 to –2·32 
 
 
16·859 
9·646, 24·072  
p<0·001 
Quality of life 
   
AQLQ, score (N) 
    Mean change ± SD  
    95% CI 
    P-value 
236 
–0·11 ± 1·01 
–0·25 to 0·02 
 
292 
0·07 ± 0·75 
–0·02 to 0·16 
 
 
0·220 
0·086, 0·354   
p=0·001 
 
*in the 2 weeks preceding the medical visit. 
**measured at sites. 
 
Data are expressed as changes from baseline to the end of randomised treatment (week 52). All measurements were 
performed pre-bronchodilator unless otherwise indicated. 
 
N = number of patients; ACQ = Asthma Control Questionnaire; AQLQ = Asthma-Related Quality of Life 
Questionnaire. 
 
Morning PEF, Evening PEF, Asthma Symptoms Score, % days without symptoms, rescue Medication and % of Day 
without Rescue Medication are analysed excluding from the analysis the diary card measurements where the patients 
entered less than 75% data in the last 2 weeks before the visit (i.e. < 10 days over the 2 weeks preceding a study visit). 
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Table 3. Treatment-emergent adverse events (TEAEs) reported in more than 2% of patients in 
either group  
 
Symptom or disease  
 
PRN 
budesonide/ 
formoterol 
(N=419) 
 
Regular  
budesonide/ 
formoterol  
(N=437) 
 
 
 
 
P-value 
 N (%) N (%)  
Asthma worsening 48 (11·5) 40 (9·2) 0·268 
Headache 27 (6·4) 30 (6·9) 0·805 
Rhinitis 25 (6·0) 25 (5·7) 0·878 
Bronchitis 23 (5·5) 24 (5·5) 0·999 
Pyrexia 21 (5·0) 18 (4·1) 0·531 
Influenza 17 (4·1) 19 (4·3) 0.832 
Nasopharyngitis 11 (2·6) 22 (5·0)  0·067 
Cough 15 (3·6) 16 (3·7) 0·949 
Oropharyngeal pain 6 (1·4) 16 (3·7) 0·039  
Back pain 11 (2·6) 10 (2·3) 0·750 
Pharyngitis 9 (2·1) 5 (1·1) 0·247 
Arthralgia 6 (1·4) 9 (2·1) 0·484 
 
N = number of patients; TEAE = treatment-emergent adverse event. 
Data are expressed as number (%) of patients for each TEAE (safety population). 
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FIGURE LEGENDS 
 
Figure 1. Summary of patient disposition. AEs = adverse events; LR = lack of therapeutic response 
resulting in unacceptable risk; AR = abnormal results that constitute a risk to the patient; PV = 
protocol violations; EC = development of an exclusion criterion; PC = poor compliance to study 
drug; BI = subject’s best interest (based on investigator’s judgment); CW = consent withdrawn; OR 
= other reasons; MI = missing. 
 
Figure 2.  Kaplan-Meier plots for the time to treatment failure (ITT and PP populations). Left 
panel: Kaplan-Meier plot for the time to treatment failure by treatment group in the ITT population. 
Right panel: Kaplan-Meier plot for the time to treatment failure by treatment group in the PP 
population.  
 
Figure 3. Effects of baseline risk factors or covariates on the probability of treatment failure overall 
and in the two groups (ITT population).  
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Panel 
Research in context 
We identified trials of the Single inhaler Maintenance and Reliever Therapy (SMART) and 
rescue/as needed (PRN) medication in asthma with a systematic search of Medline and 
handsearching of respiratory journals and meeting abstracts. We searched for (“single inhaler”, 
“Symbicort”, “Seretide”, “Advair”, “Viani”, “Fostair”, or “Clenil Forte”) or (“inhaled 
corticosteroid”, “ICS”, “fluticasone”, “FP”, “Flixotide”, “budesonide”, “BUD”, “Pulmicort”, 
“beclomethasone”, or “Becotide”) and (“long acting beta agonist”, “beta-agonist”, “LABA”, 
“salmeterol”, “Serevent”, “formoterol”, “Oxis”, “Foradil”, or “Atimos”). Searches started before 
the study was designed and the writing of the protocol, and the search dates were from Jan 1, 1950, 
until Aug 31, 2014. Of the complete list of references obtained, we selected those relevant to our 
study, particularly those on the Single inhaler Maintenance and Reliever Therapy (SMART) and 
rescue/as needed (PRN) medication in asthma, and those on rescue ICS/LABA combinations in a 
single inhaler for mild asthma were included. Since our study is the first, to the best of our 
knowledge, of the rescue budesonide–formoterol combination in a single inhaler for moderate 
asthma, no specific reference was found. By contrast, all original studies on prn only 
ICS/formoterol combinations in a single inhaler for mild asthma and ICS/formoterol used as 
maintenance and reliever therapy (SMART therapy) for moderate to severe asthma were reviewed 
and the most important quoted. While all previous studies showed that prn ICS/formoterol 
combination was more effective as compared to prn fast-acting bronchodilator,  our study showed 
that prn ICS/formoterol combination without any regular treatment either with ICS or ICS/LABA 
is less effective compared to the guidelines recommended regular treatment with ICS/LABA plus 
prn fast-acting bronchodilator.  
Interpretation 
Current guidelines recommend regular inhaled long-acting beta2-agonist/corticosteroid 
(LABA/ICS) plus rapid-acting β2 agonists or ICS/formoterol rescue symptom driven for the 
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treatment of moderate asthma not controlled by regular ICS. In this study investigated whether a 
simpler rescue symptom-driven (PRN) budesonide/formoterol combination would be as effective 
as the regular budesonide/formoterol combination plus symptom-driven terbutaline. The findings 
of our trial confirm this guideline recommendation by showing that the PRN inhaled 
budesonide/formoterol therapy is less effective than the regular budesonide/formoterol therapy in 
moderate asthmatic patients not controlled by ICS alone or adequately controlled by LABA(ICS 
combination. The idea of testing a PRN only LABA/ICS combination treatment in moderate 
asthma came from previous studies that showed that inhaled PRN SABA/ICS or inhaled PRN 
LABA/ICS combination were effective respectively to maintain under control intermittent or mild 
asthma and that the SMART therapy was more effective than regular LABA/ICS therapy in 
moderate to severe asthma. 
 
 
